USA flag logo/image

An Official Website of the United States Government

Analysis of Circulating Cancer Cells Early in Disease

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
55597 		Program Year/Program:
2001 / SBIR
Agency Tracking Number:
2R44CA083598-02 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Immunicon Corporation
Immunicon Corporation 3401 Masons Mill Rd, Ste 100 Huntingdon Valley, PA 19006
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2001
Title: Analysis of Circulating Cancer Cells Early in Disease
Agency: HHS
Contract: N/A
Award Amount: $309,500.00
 

Abstract:

DESCRIPTION: (provided by applicant) The long term objective of this proposal is commercialization of a test for the management of cancer. Immunicon has developed a sensitive test for detecting tumor cells in peripheral blood. This test uses ferrofluids and magnetic separation technology for tumor cell enrichment and multidimensional flow cytometry for cell analysis. Clinical data show that tumor cells exist in the blood of breast cancer patients. One limitation of this test is that flow cytometry does not confirm the identity of the events that are detected. Morphologic features of cells of immunophenotypically identified events can improve the specificity of the test. These features can be obtained using multicolor fluorescent microscopy. The quantity of ferrofluid used to capture tumor cells from blood, however, can obscure the cell. Phase I feasibility data show that proposed new methods helped to decrease ferrofluid without sacrificing the sensitivity of the test and the proposed objectives were achieved. Feasibility data also shows that incorporating these methods into new assay procedures permits microscopy analysis - a significant breakthrough. The aim of this Phase II proposal is to adapt these new procedures which incorporate the Phase I developments to further develop and validate the test to detect cancer cells present in blood using multi color fluorescent microscopy. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Principal Investigator:

Chandra Rao

Business Contact:


2159380100
IMMUNICON@IMMUNICON.COM
Small Business Information at Submission:

IMMUNICON CORPORATION
1310 MASONS MILL II HUNTINGDON VALLEY, PA 19006

EIN/Tax ID: 232269490
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No